title: Monkey adrenal chromaffin cells express α6β4* nicotinic acetylcholine receptors.
abstract: Nicotinic acetylcholine receptors (nAChRs) that contain α6 and β4 subunits have been demonstrated functionally in human adrenal chromaffin cells, rat dorsal root ganglion neurons, and on noradrenergic terminals in the hippocampus of adolescent mice. In human adrenal chromaffin cells, α6β4* nAChRs (the asterisk denotes the possible presence of additional subunits) are the predominant subtype whereas in rodents, the predominant nAChR is the α3β4* subtype. Here we present molecular and pharmacological evidence that chromaffin cells from monkey (Macaca mulatta) also express α6β4* receptors. PCR was used to show the presence of transcripts for α6 and β4 subunits and pharmacological characterization was performed using patch-clamp electrophysiology in combination with α-conotoxins that target the α6β4* subtype. Acetylcholine-evoked currents were sensitive to inhibition by BuIA[T5A,P6O] and MII[H9A,L15A]; α-conotoxins that inhibit α6-containing nAChRs. Two additional agonists were used to probe for the expression of α7 and β2-containing nAChRs. Cells with currents evoked by acetylcholine were relatively unresponsive to the α7-selctive agonist choline but responded to the agonist 5-I-A-85380. These studies provide further insights into the properties of natively expressed α6β4* nAChRs.
authors.affiliation: Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Hernández-Vivanco
authors.affiliation: Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Arik J
authors.initials: AJ
authors.lastname: Hone
authors.affiliation: Department of Biology, University of Utah, Salt Lake City, Utah, United States of America.
authors.forename: Mick L
authors.initials: ML
authors.lastname: Scadden
authors.affiliation: Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Carmona-Hidalgo
authors.affiliation: George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, United States of America; Department of Biology, University of Utah, Salt Lake City, Utah, United States of America; Department of Psychiatry, University of Utah, Salt Lake City, Utah, United States of America.
authors.forename: J Michael
authors.initials: JM
authors.lastname: McIntosh
authors.affiliation: Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Almudena
authors.initials: A
authors.lastname: Albillos
mesh_terms: D000818:Animals; D019439:Chromaffin Cells / Q000378:metabolism*; D020916:Conotoxins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects; D000882:Haplorhini; D018408:Patch-Clamp Techniques; D016133:Polymerase Chain Reaction; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism*
chemical_list: D020916:Conotoxins; D011978:Receptors, Nicotinic; C515221:alpha-conotoxin BuIA, Conus bullatus; C098872:alpha-conotoxin MII
references.citation: Brain Res. 2014 Jan 13;1542:1-11
references.pmid: 24157862
references.citation: J Biol Chem. 2008 Apr 25;283(17):11625-32
references.pmid: 18299323
references.citation: FASEB J. 2012 Oct;26(10):4102-10
references.pmid: 22751014
references.citation: Physiol Rev. 2009 Jan;89(1):73-120
references.pmid: 19126755
references.citation: Mol Pharmacol. 2000 Mar;57(3):642-9
references.pmid: 10692507
references.citation: J Biol Chem. 2013 Aug 30;288(35):25428-25439
references.pmid: 23846688
references.citation: Neuropharmacology. 2011 May;60(6):861-8
references.pmid: 21232546
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):231-7
references.pmid: 15316087
references.citation: J Neurosci. 1997 Jul 15;17(14):5263-70
references.pmid: 9204910
references.citation: Br J Pharmacol. 2012 Feb;165(4):908-21
references.pmid: 21790533
references.citation: Placenta. 2005 Nov;26(10):735-46
references.pmid: 16226123
references.citation: Br J Pharmacol. 1984 Apr;81(4):599-610
references.pmid: 6326921
references.citation: Biochem Pharmacol. 2013 Oct 15;86(8):1194-200
references.pmid: 23811312
references.citation: Br J Pharmacol. 2011 May;163(2):313-29
references.pmid: 21232042
references.citation: J Neurochem. 2010 Mar;112(5):1210-22
references.pmid: 20002295
references.citation: FASEB J. 2010 Dec;24(12):5113-23
references.pmid: 20739611
references.citation: J Pharmacol Exp Ther. 2009 Nov;331(2):547-54
references.pmid: 19644040
references.citation: J Neurochem. 2009 Oct;111(1):80-9
references.pmid: 19650873
references.citation: FASEB J. 2012 Feb;26(2):917-26
references.pmid: 22024738
references.citation: J Biol Chem. 2005 Jan 7;280(1):80-7
references.pmid: 15520009
references.citation: J Neurochem. 1998 Mar;70(3):1069-76
references.pmid: 9489727
references.citation: Mol Pharmacol. 2007 Jul;72(1):52-61
references.pmid: 17409284
references.citation: J Neurosci. 2008 Nov 19;28(47):12318-27
references.pmid: 19020025
references.citation: Mol Pharmacol. 2004 Jun;65(6):1526-35
references.pmid: 15155845
references.citation: J Biol Chem. 2011 Nov 4;286(44):37976-37989
references.pmid: 21832048
references.citation: J Physiol. 2009 Jan 15;587(2):345-61
references.pmid: 19047205
references.citation: Mol Pharmacol. 1998 Aug;54(2):322-33
references.pmid: 9687574
references.citation: J Biol Chem. 1980 Nov 10;255(21):10144-56
references.pmid: 7430118
references.citation: Eur J Neurosci. 2003 Jun;17(11):2313-22
references.pmid: 12814364
references.citation: Mol Pharmacol. 2013 Sep;84(3):393-406
references.pmid: 23788655
references.citation: Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1408-15
references.pmid: 18952912
references.citation: Mol Pharmacol. 2011 Jan;79(1):126-40
references.pmid: 20923852
references.citation: Br J Pharmacol. 2011 May;163(2):346-57
references.pmid: 21232049
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1235-46
references.pmid: 17825262
references.citation: Eur J Pharmacol. 2005 Nov 7;524(1-3):11-8
references.pmid: 16266703
references.citation: Auton Neurosci. 2004 Jun 30;113(1-2):32-42
references.pmid: 15296793
references.citation: Mol Pharmacol. 2004 Apr;65(4):944-52
references.pmid: 15044624
references.citation: Respir Res. 2004 Dec 10;5:27
references.pmid: 15588326
references.citation: Neuropharmacology. 2000 Oct;39(13):2570-90
references.pmid: 11044728
references.citation: J Comp Neurol. 2002 Mar 12;444(3):260-74
references.pmid: 11840479
references.citation: FASEB J. 2012 Jan;26(1):346-54
references.pmid: 21917987
references.citation: Mol Pharmacol. 2005 Jan;67(1):32-41
references.pmid: 15470079
references.citation: Eur J Neurosci. 1996 Nov;8(11):2428-39
references.pmid: 8950106
references.citation: J Neurochem. 2011 Jan;116(1):105-21
references.pmid: 21054386
references.citation: Eur J Neurosci. 2000 Oct;12(10):3664-74
references.pmid: 11029636
references.citation: Mol Pharmacol. 1997 Feb;51(2):320-7
references.pmid: 9203638
references.citation: Neuropharmacology. 2008 Jun;54(8):1189-200
references.pmid: 18448138
references.citation: Mol Pharmacol. 2005 Dec;68(6):1656-68
references.pmid: 16129735
references.citation: J Biol Chem. 1996 Mar 29;271(13):7522-8
references.pmid: 8631783
references.citation: J Neurochem. 2004 Feb;88(3):668-79
references.pmid: 14720216
references.citation: J Neurosci. 2001 Mar 1;21(5):1452-63
references.pmid: 11222635
references.citation: J Neurophysiol. 2001 Oct;86(4):1773-82
references.pmid: 11600638
references.citation: J Clin Invest. 2003 Jan;111(1):81-90
references.pmid: 12511591
references.citation: Neuropsychopharmacology. 2010 Feb;35(3):665-73
references.pmid: 19890263
references.citation: Eur J Neurosci. 1998 Jan;10(1):172-8
references.pmid: 9753124